Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities

FHS
June 16, 2023
12:31 pm

Catalen today announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.

Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma

NASHVILLE, Tenn. — An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small

November 12, 2023

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomized Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder | Psychedelic Invest

VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio“) is pleased to announce final regulatory approvals have been

March 5, 2024

Numinus CEO Expects MAPS Phase 3 MDMA-Assisted Therapy Readout To Galvanize The Sector

On this new Psychedelic Series Podcast, TDR Founder Shadd Dales spoke with Payton Nyquvest, CEO of Numinus Wellness Inc. (TSE: NUMI) (OTCMKTS: NUMIF). The podcast focused on the near term roadmap,

August 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.